journal
https://read.qxmd.com/read/38388707/adjuvant-chemotherapy-improves-os-in-utuc
#1
JOURNAL ARTICLE
David Killock
No abstract text is available yet for this article.
February 22, 2024: Nature Reviews. Clinical Oncology
https://read.qxmd.com/read/38383759/fda-approvals-in-2023-biomarker-positive-subsets-equipoise-and-verification-of-benefit
#2
JOURNAL ARTICLE
Kelly J Norsworthy, Rosa J Lee-Alonzo, Richard Pazdur
No abstract text is available yet for this article.
February 21, 2024: Nature Reviews. Clinical Oncology
https://read.qxmd.com/read/38378898/targeting-atr-in-patients-with-cancer
#3
REVIEW
Natalie Y L Ngoi, Patrick G Pilié, Daniel J McGrail, Michal Zimmermann, Katharina Schlacher, Timothy A Yap
Pharmacological inhibition of the ataxia telangiectasia and Rad3-related protein serine/threonine kinase (ATR; also known as FRAP-related protein (FRP1)) has emerged as a promising strategy for cancer treatment that exploits synthetic lethal interactions with proteins involved in DNA damage repair, overcomes resistance to other therapies and enhances antitumour immunity. Multiple novel, potent ATR inhibitors are being tested in clinical trials using biomarker-directed approaches and involving patients across a broad range of solid cancer types; some of these inhibitors have now entered phase III trials...
February 20, 2024: Nature Reviews. Clinical Oncology
https://read.qxmd.com/read/38374435/tabelecleucel-is-effective-in-ebv-positive-lymphoproliferative-disease
#4
JOURNAL ARTICLE
Diana Romero
No abstract text is available yet for this article.
February 19, 2024: Nature Reviews. Clinical Oncology
https://read.qxmd.com/read/38365954/kn046-shows-tolerability-and-activity-in-tnbc
#5
JOURNAL ARTICLE
Peter Sidaway
No abstract text is available yet for this article.
February 16, 2024: Nature Reviews. Clinical Oncology
https://read.qxmd.com/read/38326563/dendritic-cells-as-orchestrators-of-anticancer-immunity-and-immunotherapy
#6
REVIEW
Ignacio Heras-Murillo, Irene Adán-Barrientos, Miguel Galán, Stefanie K Wculek, David Sancho
Dendritic cells (DCs) are a heterogeneous group of antigen-presenting innate immune cells that regulate adaptive immunity, including against cancer. Therefore, understanding the precise activities of DCs in tumours and patients with cancer is important. The classification of DC subsets has historically been based on ontogeny; however, single-cell analyses are now additionally revealing a diversity of functional states of DCs in cancer. DCs can promote the activation of potent antitumour T cells and immune responses via numerous mechanisms, although they can also be hijacked by tumour-mediated factors to contribute to immune tolerance and cancer progression...
February 7, 2024: Nature Reviews. Clinical Oncology
https://read.qxmd.com/read/38316989/adjuvant-sintilimab-effective-in-high-risk-hcc
#7
JOURNAL ARTICLE
Peter Sidaway
No abstract text is available yet for this article.
February 5, 2024: Nature Reviews. Clinical Oncology
https://read.qxmd.com/read/38302646/personalized-neoantigen-mrna-vaccine-mitigates-melanoma-recurrence
#8
JOURNAL ARTICLE
David Killock
No abstract text is available yet for this article.
February 1, 2024: Nature Reviews. Clinical Oncology
https://read.qxmd.com/read/38302645/promising-early-results-with-car-nk-cells
#9
JOURNAL ARTICLE
Diana Romero
No abstract text is available yet for this article.
February 1, 2024: Nature Reviews. Clinical Oncology
https://read.qxmd.com/read/38291134/sotorasib-dosing-and-incremental-cost-ineffectiveness-implications-and-lessons-for-stakeholders
#10
JOURNAL ARTICLE
Garth W Strohbehn, Mark J Ratain
No abstract text is available yet for this article.
January 30, 2024: Nature Reviews. Clinical Oncology
https://read.qxmd.com/read/38278876/combination-strategies-for-advanced-stage-urothelial-carcinoma-a-paradigm-shift
#11
JOURNAL ARTICLE
Nimira Alimohamed, Srikala S Sridhar
No abstract text is available yet for this article.
January 26, 2024: Nature Reviews. Clinical Oncology
https://read.qxmd.com/read/38278875/repotrectinib-effective-in-ros1-fusion-positive-nsclc
#12
JOURNAL ARTICLE
Peter Sidaway
No abstract text is available yet for this article.
January 26, 2024: Nature Reviews. Clinical Oncology
https://read.qxmd.com/read/38278874/braf-a-tumour-agnostic-drug-target-with-lineage-specific-dependencies
#13
REVIEW
Aphrothiti J Hanrahan, Ziyu Chen, Neal Rosen, David B Solit
In June 2022, the FDA granted Accelerated Approval to the BRAF inhibitor dabrafenib in combination with the MEK inhibitor trametinib for the treatment of adult and paediatric patients (≥6 years of age) with unresectable or metastatic BRAFV600E -mutant solid tumours, except for BRAFV600E -mutant colorectal cancers. The histology-agnostic approval of dabrafenib plus trametinib marks the culmination of two decades of research into the landscape of BRAF mutations in human cancers, the biochemical mechanisms underlying BRAF-mediated tumorigenesis, and the clinical development of selective RAF and MEK inhibitors...
January 26, 2024: Nature Reviews. Clinical Oncology
https://read.qxmd.com/read/38243022/harnessing-neoantigen-specific-t-cells-for-precision-cancer-immunotherapy
#14
JOURNAL ARTICLE
Marco Donia, Inge Marie Svane
No abstract text is available yet for this article.
January 19, 2024: Nature Reviews. Clinical Oncology
https://read.qxmd.com/read/38195910/lung-cancer-in-patients-who-have-never-smoked-an-emerging-disease
#15
REVIEW
Jaclyn LoPiccolo, Alexander Gusev, David C Christiani, Pasi A Jänne
Lung cancer is the most common cause of cancer-related deaths globally. Although smoking-related lung cancers continue to account for the majority of diagnoses, smoking rates have been decreasing for several decades. Lung cancer in individuals who have never smoked (LCINS) is estimated to be the fifth most common cause of cancer-related deaths worldwide in 2023, preferentially occurring in women and Asian populations. As smoking rates continue to decline, understanding the aetiology and features of this disease, which necessitate unique diagnostic and treatment paradigms, will be imperative...
January 9, 2024: Nature Reviews. Clinical Oncology
https://read.qxmd.com/read/38191924/management-of-patients-with-advanced-stage-her2-positive-breast-cancer-current-evidence-and-future-perspectives
#16
REVIEW
Antonio Marra, Sarat Chandarlapaty, Shanu Modi
Amplification and/or overexpression of ERBB2, the gene encoding HER2, can be found in 15-20% of invasive breast cancers and is associated with an aggressive phenotype and poor clinical outcomes. Relentless research efforts in molecular biology and drug development have led to the implementation of several HER2-targeted therapies, including monoclonal antibodies, tyrosine-kinase inhibitors and antibody-drug conjugates, constituting one of the best examples of bench-to-bedside translation in oncology. Each individual drug class has improved patient outcomes and, importantly, the combinatorial and sequential use of different HER2-targeted therapies has increased cure rates in the early stage disease setting and substantially prolonged survival for patients with advanced-stage disease...
January 8, 2024: Nature Reviews. Clinical Oncology
https://read.qxmd.com/read/38191923/exploring-the-next-generation-of-antibody-drug-conjugates
#17
REVIEW
Kyoji Tsuchikama, Yasuaki Anami, Summer Y Y Ha, Chisato M Yamazaki
Antibody-drug conjugates (ADCs) are a promising cancer treatment modality that enables the selective delivery of highly cytotoxic payloads to tumours. However, realizing the full potential of this platform necessitates innovative molecular designs to tackle several clinical challenges such as drug resistance, tumour heterogeneity and treatment-related adverse effects. Several emerging ADC formats exist, including bispecific ADCs, conditionally active ADCs (also known as probody-drug conjugates), immune-stimulating ADCs, protein-degrader ADCs and dual-drug ADCs, and each offers unique capabilities for tackling these various challenges...
January 8, 2024: Nature Reviews. Clinical Oncology
https://read.qxmd.com/read/38191922/myeloid-derived-suppressor-cells-in-cancer-and-cancer-therapy
#18
REVIEW
Samantha A Lasser, Feyza G Ozbay Kurt, Ihor Arkhypov, Jochen Utikal, Viktor Umansky
Anticancer agents continue to dominate the list of newly approved drugs, approximately half of which are immunotherapies. This trend illustrates the considerable promise of cancer treatments that modulate the immune system. However, the immune system is complex and dynamic, and can have both tumour-suppressive and tumour-promoting effects. Understanding the full range of immune modulation in cancer is crucial to identifying more effective treatment strategies. Myeloid-derived suppressor cells (MDSCs) are a heterogeneous population of myeloid cells that develop in association with chronic inflammation, which is a hallmark of cancer...
January 8, 2024: Nature Reviews. Clinical Oncology
https://read.qxmd.com/read/38191921/tumour-infiltrating-lymphocyte-therapy-for-patients-with-advanced-stage-melanoma
#19
REVIEW
Sebastian Klobuch, Tom T P Seijkens, Ton N Schumacher, John B A G Haanen
Immunotherapy with immune-checkpoint inhibitors (ICIs) and targeted therapy with BRAF and MEK inhibitors have revolutionized the treatment of melanoma over the past decade. Despite these breakthroughs, the 5-year survival rate of patients with advanced-stage melanoma is at most 50%, emphasizing the need for additional therapeutic strategies. Adoptive cell therapy with tumour-infiltrating lymphocytes (TILs) is a therapeutic modality that has, in the past few years, demonstrated long-term clinical benefit in phase II/III trials involving patients with advanced-stage melanoma, including those with disease progression on ICIs and/or BRAF/MEK inhibitors...
January 8, 2024: Nature Reviews. Clinical Oncology
https://read.qxmd.com/read/38182900/-contribution-of-component-and-the-perioperative-immune-checkpoint-inhibitor-precedent
#20
JOURNAL ARTICLE
Garth W Strohbehn, Bishal Gyawali
No abstract text is available yet for this article.
January 5, 2024: Nature Reviews. Clinical Oncology
journal
journal
20200
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.